Total prion protein levels in the cerebrospinal fluid are reduced in patients with various neurological disorders by Meyne, F et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2009
Total prion protein levels in the cerebrospinal fluid are reduced
in patients with various neurological disorders
Meyne, F; Gloeckner, S F; Ciesielczyk, B; Heinemann, U; Krasnianski, A; Meissner,
B; Zerr, I
Meyne, F; Gloeckner, S F; Ciesielczyk, B; Heinemann, U; Krasnianski, A; Meissner, B; Zerr, I (2009). Total prion
protein levels in the cerebrospinal fluid are reduced in patients with various neurological disorders. Journal of
Alzheimer's Disease:Epub ahead of print.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Journal of Alzheimer's Disease 2009, :Epub ahead of print.
Meyne, F; Gloeckner, S F; Ciesielczyk, B; Heinemann, U; Krasnianski, A; Meissner, B; Zerr, I (2009). Total prion
protein levels in the cerebrospinal fluid are reduced in patients with various neurological disorders. Journal of
Alzheimer's Disease:Epub ahead of print.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Journal of Alzheimer's Disease 2009, :Epub ahead of print.
Total prion protein levels in the cerebrospinal fluid are reduced
in patients with various neurological disorders
Abstract
We performed a study on levels of the total prion protein (PrP) in humans affected by different
neurological diseases and assessed the influence of several factors such as age, gender, and disease
severity on the cerebrospinal fluid PrP levels. PrP-ELISA technique was used to analyze cerebrospinal
fluid (CSF) samples. 293 CSF samples of patients with Creutzfeldt-Jakob-disease (CJD), Alzheimer's
disease, dementia with Lewy-bodies, Parkinson's disease, multiple sclerosis, cerebral ischemia,
generalized epileptic seizures, and meningitis and encephalitis in comparison to controls were analyzed.
We found a significant reduction of CSF PrP levels in patients suffering from all neurodegenerative
disorders analyzed. This group exhibited mean PrP values of 164 ng/ml while non-neurodegenerative
disorder patients and healthy controls showed PrP levels of 208 ng/ml and 226 ng/ml, respectively. CSF
levels correlated with disease severity in CJD, Alzheimer's disease, and dementia with Lewy-bodies.
The finding of decreased PrP levels in the CSF of patients not only with CJD but also in other
neurodegenerative disorders is intriguing. Age-, gender-, and genetic-specific factors might be involved
in the PrP<formula>;{c}</formula> regulation.
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Abstract. We performed a study on levels of the total prion protein (PrP) in humans affected by different neurological diseases and
assessed the influence of several factors such as age, gender, and disease severity on the cerebrospinal fluid PrP levels. PrP-ELISA
technique was used to analyze cerebrospinal fluid (CSF) samples. 293 CSF samples of patients with Creutzfeldt-Jakob disease
(CJD), Alzheimer’s disease, dementia with Lewy-bodies, Parkinson’s disease, multiple sclerosis, cerebral ischemia, generalized
epileptic seizures, and meningitis and encephalitis in comparison to controls were analyzed. We found a significant reduction
of CSF PrP levels in patients suffering from all neurodegenerative disorders analyzed. This group exhibited mean PrP values of
164 ng/ml while non-neurodegenerative disorder patients and healthy controls showed PrP levels of 208 ng/ml and 226 ng/ml,
respectively. CSF levels correlated with disease severity in CJD, Alzheimer’s disease, and dementia with Lewy-bodies. The
finding of decreased PrP levels in the CSF of patients not only with CJD but also in other neurodegenerative disorders is intriguing.
Age-, gender-, and genetic-specific factors might be involved in the PrPc regulation.
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INTRODUCTION
The physiological prion protein (PrPc) is an evolu-
tionary highly conserved protein [1,2], which is encod-
ed in all mammalians investigated. PrPc is attached
to the outer surface of the cell membrane by a GPI-
anchor [3]. PrPc is mainly expressed in neurons but
also in other cell types such as blood cells. A posttran-
scriptional conversion of the physiological PrPc leads
to the pathologic isoform PrPSc, which is a key event
in the pathogenesis of transmissible spongiform en-
cephalopathies (TSE) in humans and animals. PrPSc
accumulates during these diseases in neural and other
tissues [4–6].
∗Corresponding author: Dr. Inga Zerr, Georg-August-Universita¨t,
Neurologische Klinik und Poliklinik, Robert-Koch-Str. 40, 37075
Go¨ttingen, Germany. E-mail: epicjd@med.uni-goettingen.de.
The functional role of the physiological PrPc is still
not fully understood. Recent studies have shown that
PrPc is a copper-binding protein with antioxidant prop-
erties [7–10]. These antioxidant properties are based on
a superoxide dismutase-like activity in the octapeptid-
region of the protein and seem to be involved in its neu-
roprotective properties by reduction of oxidative stress.
Additionally, it has been shown that neuroprotection is
triggered by inhibition of Bax-mediated neuronal apop-
tosis [11] and that PrPc is involved in the activation
of several signal transduction pathways playing an im-
portant role in neuronal survival [12–15]. Recently,
Parkin and colleagues demonstrated that cellular over-
expression of PrPc inhibits the β-secretase cleavage of
the amyloid-β protein precursor (AβPP) and reduces
amyloid-β (Aβ) formation [16].
Since knowledge regarding regulation of PrP c in hu-
mans is limited, we analyzed the total PrP levels in
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the cerebrospinal fluid (CSF) of patients with vari-
ous neurological diseases. This approach was chosen
since the composition of proteins in the CSF is as-
sumed to reflect pathological processes in the brain.
We used CSF samples from patients with various neu-
rodegenerative diseases such as Creutzfeldt-Jakob dis-
ease (CJD), Alzheimer’s disease (AD), dementia with
Lewy-bodies (DLB), Parkinson’s disease (PD), and al-
so non-degenerative diseases such as epileptic seizures,
meningitis and encephalitis, multiple sclerosis (MS),
and cerebral ischemia in comparison to controls with-
out any organic diseases of the central nervous system.
Special focus was given to the influence of the dis-
ease course, age and gender, and the PRNP M129V
polymorphism in CJD patients on PrP levels and to the
question of whether PrP can function as a diagnostic
biomarker, similar to commonly used biomarkers like
Aβ1−42 and tau protein in dementia diagnosis.
METHODS
Cerebrospinal fluid samples
CSF samples were collected in the Neurochemistry
Laboratory at the Department of Neurology, Georg-
August University, Goettingen between January 1997
and December 2005. The patients received inpatient
or outpatient treatment at the Department of Neurology
and were given a lumbar puncture during diagnostic
procedure. Additionally, CSF samples were sent from
referring German hospitals to the National TSE Refer-
ence Center at the Department of Neurology in order
to determine 14-3-3 proteins for a differential diagno-
sis of CJD. Only CSF samples which were centrifuged
and immediately frozen after collection and stored at
−80◦C until processing were used in this study. Blood
contaminated samples were excluded from analysis.
Informed consent was available for all patients.
Patients
Controls: These patients had lumbar punctures with
normal CSF findings. An organic disease of the cen-
tral nervous system was excluded during the diagnos-
tic workup. Diagnoses in this group of patients were
mainly depression, polyneuropathy, vertigo, or pain
syndromes.
Creutzfeldt-Jakob disease: All individuals in this
group were deceased and postmortem neuropatholog-
ical examination confirmed the diagnosis, when per-
formed. Only definite or clinically probable sporadic
(after exclusion of PRNP mutation) cases were includ-
ed in the analyses. Codon 129 genotype (rs1799990)
was determined as described elsewhere [17].
Alzheimer’s disease: The diagnosis in these patients
based on the NINCDS-ARDRA criteria [18].
Dementia with Lewy-bodies: The diagnosis was
based on criteria of the consensus conference of
1996 [19].
Parkinson’s disease: The diagnosis was based on
criteria of ICD-10 [20].
Epileptic seizures: We analyzed the CSF of patients
with generalized epileptic seizures. The mean time
of lumbar puncture was at day 3 ± 2. Patients with
symptomatic seizures such as space occupying lesions
or encephalitis were excluded.
Cerebral ischemia: Cerebral ischemia was con-
firmed by brain imaging analyses (either computed to-
mography or magnetic resonance imaging). The mean
time of lumbar puncture was 7 ± 4 after the ischemia-
event.
Multiple sclerosis: This group was heterogeneous,
including patients with primary progressive and relaps-
ing forms. The lumbar puncture was performed at the
time of initial diagnosis for clinical workup. McDonald
criteria were used for the diagnoses [21].
Meningitis/encephalitis: The diagnosis was based
on ICD-10 [20]. This group consisted of meningitis
and encephalitis affected by various bacterial and viral
pathogens.
The number of patients in each group and age and
gender distribution is given in Table 1.
PrP ELISA
We used Platelia BSE-Detection Kit (BIO-RAD
Laboratories GmbH, Munich, Germany) according to
the manufacturer’s instructions. This kit is based on
ELISA techniques and is employed as a rapid BSE test
for qualitative determination of PrPSc in the brain stem
tissue of cattle and sheep. For our experiments, we
omitted the Proteinase K digestion step, which digests
PrPc, but not PrPSc, since our aim was to determine
total PrP levels in the CSF (in subjects with prion dis-
eases PrPc plus potentially extremely low amount of
PrPSc) [22]. CSF samples were applied undiluted. Cal-
ibration was performed with recombinant PrP (Prion-
ics, Zurich, Switzerland) and a calibration curve was
calculated. This curve was used to determine the PrP
concentrations based on the values obtained from the
ELISA assay. The signal was measured at 450 nm with
a 1420 Multilabel Counter Victor 2 (Wallac).
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Table 1
Core clinical data and PrP results
n M/F All age, median Age, mean ± SD PrPc ng/ml PrPc ng/ml PrPc ng/ml
mean ± SD mean ± SD mean ± SD mean ± SD
male female all male female
Neurodegenerative diseases
CJD 117 48/69 64 ± 11 62 ± 9 66 ± 11 160 ± 76 160 ± 68 160 ± 81
AD 29 11/18 64 ± 10 62 ± 11 65 ± 10 177 ± 80 155 ± 64 191 ± 87
DLB 21 13/8 76 ± 7 75 ± 6 77 ± 8 162 ± 66 169 ± 72 150 ± 55
PD 27 12/9 70 ± 9 72 ± 7 66 ± 12 174 ± 81 156 ± 87 208 ± 70
Others
Ischemia 21 12/9 64 ± 13 64 ± 10 63 ± 17 193 ± 77 189 ± 92 198 ± 56
MS 11 4/7 44 ± 12 48 ± 8 41 ± 14 226 ± 49 226 ± 62 225 ± 45
Meningitis & encephalitis 14 9/5 48 ± 23 50 ± 25 46 ± 20 222 ± 82 218 ± 70 229 ± 110
Epileptic seizures 13 8/5 33 ± 18 41 ± 21 28 ± 15 201 ± 63 217 ± 67 176 ± 52
Controls
All 40 18/22 49 ± 19 53 ± 19 45 ± 18 226 ± 79 254 ± 91 203 ± 61
>40y 24 13/11 62 ± 12 63 ± 12 60 ± 12 262 ± 70 280 ± 76 241 ± 60
<40y 16 5/11 30 ± 7 29 ± 9 30 ± 6 185 ± 48 229 ± 44 165 ± 36
Aβ1−42 ELISA
Aβ1−42 levels were determined by using the hAmy-
loid β42 ELISA kit (Genetics company, Schlieren,
Switzerland, lowest detection limit 100 pg/ml).
Tau
Tau protein levels were determined by using ELISA-
techniques (INNOTEST hTau Ag; Innogenetics,
Ghent, Belgium, lowest detection limit 60 pg/ml).
Statistics
The statistical evaluation was done with SPSS for
Windows (11.5). One-way ANOVA followed by
Bonferroni-test was used to analyze the data. For
single-pair wise comparison (detection of gender dif-
ferences), the Mann-Whitney U test was used.
Correlation analyses of PrP and one potentially influ-
encing variable (e.g., age in controls) were performed
by linear regression analyses. For more than one poten-
tially influencing variable on PrP levels (e.g., disease
severity, genotype, and age), stepwise multiple linear
regression analyses were used to assess the influence
of a single parameter (all results were given as beta
coefficients). For these analyses, PrP was used as crite-
rion variable and considered (predictor) variables were
given in parentheses. All values were shown as means
± standard deviation (SD). Values of p < 0.05 were
considered to be significant.
For graphical presentation of the statistical analyses,
we used the BOX-and Whisker-Plot. In order to evalu-
ate the diagnostic value of PrP, we determined the op-
timal cut-off point, which gives the best balanced sen-
sitivity and specificity ratio [Youden-Index (sensitivity
+ specificity-1 = Youden)].
Criteria for severity of dementia in AD and DLB
patients
To investigate the influence of disease course on PrP
levels, we stratified the data in three groups of severity
codes. These divisions were made on the basis of the
Mini-Mental Status Examination (MMSE) or, if this
test was not available, on clinical criteria.
State 1: Minimal cognitive impairment (MMSE 24–
29 points) or mild dementia (MMSE 20–23 points);
Clinical criteria – not disoriented or possibly mild dis-
oriented regarding time.
State 2: Moderate dementia (MMSE 10–19 points);
Clinical criteria – moderate disoriented regarding time
and/or place, not disoriented regarding situation and
person.
State 3: Severe dementia (MMSE 0–9 points); Clin-
ical criteria – severe disoriented regarding time, place
and situation, possibly disoriented regarding person.
Criteria for disease severity in CJD patients
We divided the time of lumbar puncture to disease
onset in each patient by the total duration of the disease.
Thus, we classified patients in three categories accord-
ing to whether they underwent lumbar puncture in the
first (time of lumbar puncture to disease onset/total du-
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Fig. 1. PrP-CSF levels in patients with various neurodegenerative disorders and dementia.
ration of the disease < 0.33), second (0.33–0.66), or
third (> 0.66) state of the disease.
This study was approved by the local ethics commit-
tee.
RESULTS
PrP levels in the CSF
Table 1 displays the mean CSF levels of PrP in our
patients. The data for controls were stratified by age 40
and two groups were analyzed (controls younger than
40 at lumbar puncture, “younger controls”, and controls
older than 40 at lumbar puncture, “older controls”)
(Table 1). Because of a potential influence of age on
PrP levels, the values in special patient groups were
first compared to the whole control group and then to
older or younger controls, respectively.
Neurodegenerative diseases (CJD, AD, DLB, and
PD) had mean PrP levels of 164 ng/ml CSF. They
were significantly lower in comparison to the whole
group of controls (p < 0.001) and to the whole group
of non-neurodegenerative diseases (p < 0.001). For
the group of controls, we determined mean PrP lev-
els of 226 ng/ml (Table 1). Comparing each neu-
rodegenerative disease with the older control group,
we found significantly reduced PrP CSF levels (p <
0.001 for CJD, DLB, and PD and p = 0.001 for
AD) (Fig. 1). No differences were observed between
CJD, AD, DLB, and PD. Non-neurodegenerative/non-
vascular diseases (MS, meningitis and encephalitis,
epileptic seizures) had mean PrP levels of 216 ng/ml
(Table 1). No differences were seen between MS and
meningitis/encephalitis compared to older as well as
younger control patients. Additionally, we could not
find differences between CSF PrP levels in epileptic
seizure patients (this group consisted of young individ-
uals) in comparison to younger controls.
Finally, patients with cerebral ischemia had mean
PrP levels of 193 ng/ml (Table 1). Although some
individuals in this group were characterized by low PrP-
levels, statistical significant differences in PrP levels
could not be confirmed when compared to the older
controls.
Influence of age and gender
A positive relationship between age and PrP levels
was observed in the control group (p = 0.01; β = 0.40)
(Fig. 2a and b). These results were mainly caused by
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Fig. 2. Influence of age on PrP levels.
the values of female controls (p = 0.001; β = 0.64)
(see Fig. 2b), since no correlation was seen between
age and PrP in male controls (p = 0.50; β = 0.17) (see
Fig. 2a). The correlation between age and PrP levels in
all other disease groups revealed no significant results.
However, significant results and trends toward signifi-
cant results could be detected in combined groups such
as all neurodegenerative groups (β = 0.16; p = 0.03)
(age; disease severity) and all non-neurodegenerative
groups (β = 0.302; p = 0.065). In contrast to the con-
trol group, the impact of gender in the disease groups
was balanced.
With exception to our younger control group (p =
0.008), PrP levels did not differ significantly between
males and females.
Influence of severity codes of dementias and disease
duration
The stratification of the data by severity codes re-
vealed lower PrP levels in patients with advanced dis-
ease stages in the group of neurodegenerative disorders
(CJD, AD, DLB; Fig. 3a,b,d,e). Levels of PrP in severe
and moderate state of dementia in comparison to older
controls and in mild state in comparison to severe state
of dementia were statistically significant (p < 0.05).
These results were mainly striking in AD and CJD
patients, but low PrP levels in advanced disease states
were also detectable in patients with DLB.
Influence of codon 129 genotype on PrP levels in CJD
The polymorphism at codon 129 was determined in
a total of 107 CJD patients. 67% (n = 72 patients)
were homozygous for methionine (MM), 18% (n = 19
patients) were heterozygous for methionine and valine
(MV), and the remaining 15% (n = 16 patients) were
homozygous for valine (VV). MM patients had mean
PrP CSF concentrations of 167 ng/ml, MV patients had
mean CSF values of 139 ng/ml, and VV homozygous
patients had a mean CSF value of 140 ng/ml. Our
results revealed significantly lower PrP concentrations
in the CSF of male patients with valine at codon 129
(β = −0.31; p = 0.05) (genotype, age, disease severi-
ty). For female CJD patients, no influence of the geno-
type was observed (β = 0.03; p = 0.79) (genotype,
age, disease severity) (Fig. 3c).
Diagnostic value of PrP
We investigated whether PrP levels in the CSF might
be used as a potential diagnostic biomarker in dementia
or PD. PrP levels lower than 200 ng/ml were found in
72% for the whole dementia group (CJD, AD, DLB,
PD) with a specificity of 88% when healthy controls
were used to calculate this parameter. Using the cut-
off, which gives the best Youden-Index, PrP levels were
decreased in 76% of CJD, 72% of AD, 76% of DLB,
and in 63% of PD samples (Table 2).
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Fig. 3. Influence of disease severity on mean PrP levels.
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Table 2
Sensitivity and specificity of PrP in different kinds of neurodegenerative diseases
in comparison to older controls
CJD AD DLB PD
Cut-off < 205 ng/ml < 200 ng/ml < 210 ng/ml < 210 ng/ml
sensitivity 76% 72% 76% 63%
specificity 88% 88% 79% 79%
Youden-index 0.64 0.60 0.55 0.42
Correlation of PrP and other biomarkers
Next, we analyzed a potential correlation between
PrP and both commonly used biomarkers for dementia
in the CSF.
Aβ1−42 values were determined in 76 samples of
CJD (mean levels 544± 359 pg/ml), 18 samples of AD
(mean levels 323± 137 pg/ml), and 8 samples of DLB
(mean levels 110 ± 36 pg/ml).
Tau values were determined in 112 samples of CJD
(mean levels 8624 ± 7252 pg/ml), 18 samples of AD
(mean levels 415± 445 pg/ml), and 12 samples of DLB
(mean levels 310 ± 107 pg/ml).
We found a significant positive correlation between
PrP and Aβ1−42 in the group of neurodegenerative dis-
eases (β = 0.25; p = 0.007), which was most apparent
in CJD (β = 0.46; p = 0.001) and AD patients (β =
0.63; p = 0.005) (Fig. 4a, 4c). In the subgroup of DLB
(β = 0.46; p = 0.25) (Fig. 4e), the correlation between
these markers was not significant.
The correlation of tau levels with PrP for the whole
group of neurodegenerative diseases did not reveal sig-
nificant results (β = 0.07; p = 0.39), but in AD
(β = 0.65; p = 0.003) and DLB patients (p = 0.006;
β = 0.74), significant correlations could be detected
(Fig. 4d, 4f). In CJD (Fig. 4b), no correlation was
observed (β = 0.11; p = 0.26 and β = 0.23; p =
0.480).
PrP levels were correlated with a semiquantitative
14-3-3 Western blot analysis (grade 0 = not detectable,
1 = weak band, 2 = intermediate band, and 3 = strong
band). There was a non-significant positive correlation
of PrP and 14-3-3 levels in CJD patients (β = −0.219,
p = 0.07). When we stratified the data by gender, the
correlation became significant for men (β = −0.504,
p = 0.014), but not for women (β = −0.0904, p =
0.535).
DISCUSSION
In this study, we investigated the CSF PrP levels
in patients with various neurological disorders such as
CJD, AD, DLB, PD, encephalitis and meningitis, cere-
bral ischemia, MS, and epileptic seizures in comparison
to controls. Our results revealed a significant decrease
of PrP CSF levels in neurodegenerative disorders ver-
sus non-neurodegenerative diseases and controls. The
decrease of PrP was greater in severe demented AD
patients than in patients with mild or moderate disease.
This was also observed in CJD; patients in advanced
disease stages had lower PrP values than patients at
early stages. The reasons for this are not fully under-
stood, since almost no study has reported on the role of
PrP in humans so far. Since we could only observe the
decrease of PrP levels in neurodegenerative disorders
and since this decrease is clearly correlated to disease
severity, our results might simply reflect brain atrophy
in these diseases, but might also be related to some oth-
er common mechanisms. The state-dependent decrease
of PrP CSF levels was observed in all neurodegenera-
tive conditions analyzed here with exception of DLB.
However, only a few patients with early DLB were an-
alyzed, which might be explained by the difficulty in
diagnosing DLB at very early stages. The low number
of mild and moderate demented patients in DLB could
be the reason that we did not observe clear correlations
but only a trend towards low levels at advanced disease
stages.
The study was motivated by recent findings of PrP
in AD. Codon 129 homozygosity is a well-known risk
factor for CJD [23] and was demonstrated recently to be
a risk factor in other dementia as well. Codon 129 ho-
mozygosity for methionine is associated with AD [24]
and for valine with a risk of cognitive decline [25,26].
A study has demonstrated that AD brains are character-
ized by an increase of intraneuronal PrPc immunoreac-
tivity compared to controls [27]. It remains unknown,
however, if the increased PrPc signals are the conse-
quence of an oxidative stress-induced upregulation of
PrPc. Another hypothesis is that increased immunore-
activity is due to a decelerated degradation of PrPc.
Furthermore, a block in intracellular trafficking of PrP c
to the cell surface could also be responsible for the in-
creased immunoreactivity [27]. Another exciting piece
of work was done by demonstrating that cellular over-
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Fig. 4. Correlation analyzes of the biomarkers in the CSF in CJD, AD, and DLB.
expression of PrPc inhibits the β-secretase cleavage of
AβPP and reduces Aβ formation [16] and that char-
acteristics of PrP isoforms in some AD brains might
differ from controls [28].
Aβ and PrPc are co-localized in senile plaques in
AD as well as in Lewy bodies in PD [29]. For AD, the
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accumulation of proteins such as Aβ plays a key role
in pathogenesis. The deposition of Aβ was discussed
to be the reason for decreased Aβ values in the CSF in
patients with AD [30]. Whether the reduction of PrP in
CSF of patients with AD and other neurodegenerative
disorders is linked to the deposition by similar mecha-
nisms in the brain tissue remains to be determined.
The finding of a positive correlation of total PrP and
total tau levels in AD is intriguing. First, we have found
a decrease in PrP levels with dementia severity in AD.
One would expect an increase in total tau levels with
dementia severity in AD and thus a negative correla-
tion on PrP and tau. However, there is no clear evi-
dence that tau levels increase during AD. In fact, most
longitudinal studies on tau levels in AD failed to show
such a correlation [31–33]. Studies on dementia sever-
ity and biomarkers point toward a correlation between
high tau levels and clinical dementia rating scores, but
data are limited and further studies on this subject are
needed [32].
We were also interested in the proportion of de-
creased PrP levels in various conditions with respect
to the usefulness as a potential biomarker. PrP lev-
els were decreased in all neurodegenerative diseases
studied here; thus, similar to other currently available
biomarkers such as Aβ1−42 and tau, it does not dis-
criminate between single conditions [34].
We analyzed several factors which might alter PrP
levels, such as age, gender, and codon 129 genotype.
PrP values in valine homozygous male patients were
determined to be lower than in MV and MM patients;
however, for female VV patients, these results could not
be demonstrated. One potential factor, which should
be analyzed in future studies, is the effect of longer
disease duration, which was repeatedly described in
valine homozygous CJD patients [35,36].
Age and gender seem to influence PrPc expres-
sion or turn-over. An age-correlated PrPc expres-
sion was found in human peripheral blood leuko-
cytes [37]. Additionally, Williams and colleagues
found age-related increase in PrPc in cerebral microves-
sels and in microvessel-depleted brain homogenate in
mice [38]. To our knowledge, there are no studies that
found an influence of gender on PrPc levels. In our
study, we found a correlation of age and PrP levels
in controls and in combined groups of neurodegenera-
tive disorders. In controls, this correlation was based
on increasing PrP levels with age in female controls.
However, the low number of healthy controls included
in this study is a limitation and the results of stratified
tests, like age and gender correlations, should be taken
with caution.
In the present study, we have found differences be-
tween PrP levels in neurodegenerative conditions and
aged controls. While we speculate that PrP levels are
reduced in neurodegenerative conditions, we cannot
entirely exclude that levels in old controls are abnor-
mally increased. However, since our control group was
comprised of patients with non-organic disorders and
peripheral (not central nervous system-related) condi-
tions, this hypothesis seems unlikely.
In conclusion, we report the first data on PrP in CSF
in humans with various neurological disorders. PrP
levels in the CSF were significantly reduced in patients
suffering from CJD, DLB, PD, and AD in comparison
to patients suffering from non-neurodegenerative dis-
eases and to healthy controls. Further work needs to be
done to clarify the role of PrPc in neurodegeneration,
but also to identify potential biochemical and structural
PrPc alterations in various conditions.
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